Kullar Ravina, Johnson Stuart, Goldstein Ellie J C
Expert Stewardship, Inc., Newport Beach, CA 92660, USA.
Hines VA Hospitl Research Service, Hines, IL 60141, USA.
Antibiotics (Basel). 2025 Aug 15;14(8):829. doi: 10.3390/antibiotics14080829.
infection (CDI) is one of the most common healthcare-associated infections in the United States with increasing rates in younger patients and those in the community. CDI incidence may also be on the rise in peripartum women. We conducted a literature review to assess the incidence and outcomes of CDI in the peripartum population and review treatment options. Peripartum patients have a high risk of complications and adverse events associated with CDI. Most patients have been treated with vancomycin or metronidazole; however, cases of patients recurring on standard treatment have been described, with patients having successful outcomes with fidaxomicin or fecal microbiota transplantation (FMT). Probiotics have been shown to be safe in peripartum women; however, the role in preventing primary and secondary CDI has not been studied. Peripartum women that develop CDI are at increased risk for complications. Treatment includes vancomycin, metronidazole, or fidaxomicin or FMT for recurrent cases.
艰难梭菌感染（CDI）是美国最常见的医疗保健相关感染之一，在年轻患者和社区患者中的发病率不断上升。围产期妇女的CDI发病率也可能在上升。我们进行了一项文献综述，以评估围产期人群中CDI的发病率和结局，并回顾治疗选择。围产期患者发生与CDI相关的并发症和不良事件的风险很高。大多数患者接受过万古霉素或甲硝唑治疗；然而，已有标准治疗后复发的病例报道，使用非达霉素或粪便微生物群移植（FMT）的患者取得了成功的治疗效果。益生菌已被证明对围产期妇女是安全的；然而，其在预防原发性和继发性CDI中的作用尚未得到研究。发生CDI的围产期妇女出现并发症的风险增加。治疗方法包括使用万古霉素、甲硝唑、非达霉素，或对复发病例采用FMT。
